Author: admin

DelveInsight’s “Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Acute Respiratory Distress Syndrome, historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Acute Respiratory Distress Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Respiratory Distress Syndrome Market Forecast

Some of the key facts of the Acute Respiratory Distress Syndrome Market Report:

• The Acute Respiratory Distress Syndrome (ARDS) market size was valued at approximately USD 1.7 billion in 2025 and is expected to grow to nearly USD 3.2 billion by 2036, registering a CAGR of 3.8% during the forecast period from 2026 to 2036.

• In January 2026, Healios submitted a clinical trial plan notification to the Pharmaceuticals and Medical Devices Agency (PMDA) for a clinical trial to be conducted in Japan as part of the Global Phase III trial (REVIVE-ARDS) for HLCM051 for the treatment of ARDS.

• In February 2026, Edesa Biotech, in its SEC filing (8K), reported that it is evaluating subgroup data for additional efficacy signals among subjects with certain comorbidities following positive results from a Phase III study of its monoclonal antibody, paridiprubart, in patients with ARDS.

• In April 2026, Edesa Biotech, in its corporate presentation, announced that the US allocated USD 117 million to evaluate three novel therapeutics for general ARDS, including Edesa’s paridiprubart.

• In February 2025, Bonus Biogroup (TASE: BONS), a late-stage biotech firm specializing in immunomodulatory and regenerative mesenchymal stromal cell (MSC) therapies, has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase III clinical trial in the U.S. The study will assess the safety and effectiveness of MesenCure™—an allogeneic cell therapy composed of enhanced MSCs derived from adipose tissue—for the treatment of respiratory distress in severely ill, hospitalized patients suffering from COVID-19-related pneumonia. MesenCure is designed to address inflammation and tissue damage.

• In January 2025, InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing anti-inflammatory therapies targeting the complement system, has announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilobelimab). This approval covers the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard care and require invasive mechanical ventilation (IMV), with or without extracorporeal membrane oxygenation (ECMO). GOHIBIC is the first and only approved therapy in the EU specifically for SARS-CoV-2-related ARDS.

• Among the 7MM, the US accounted for the largest market size of ARDS, i.e., USD ~1,300 million in 2025.

• The entry of late-stage candidates such as HLCM051 and ExoFlo (DB-2Q) is expected to intensify competition in the ARDS treatment landscape during the latter half of the forecast period.

• According to DelveInsight’s estimates, in 2025, the total number of incident cases of ARDS in the 7MM was ~980,000.

• Based on severity, moderate ARDS accounts for a higher proportion of cases compared to mild and severe ARDS.

• Pneumonia is the leading risk factor for ARDS, accounting for a significant proportion of cases, followed by sepsis.

• Key ARDS companies: Light Chain Bio, Direct Biologics, Healios/Nobel Pharma, Mesoblast, Chrysalis BioTherapeutics, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire français de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and others

• Key Acute Respiratory Distress Syndrome Therapies: Sabizabulin (Veru-111), EB05 (paridiprubart), ExoFlo (DB-001), MultiStem (HLCM051), Remestemcel-L, TP508, Traumakine, BIO-11006, MultiStem, Solnatide, VERU-111, Tradipitant, FP-025, HLCM051(MultiStem), and others

• The Acute Respiratory Distress Syndrome epidemiology based on gender analyze that the percentage of cases of Acute Respiratory Distress Syndrome (ARDS) are equal in both the genders

• The Acute Respiratory Distress Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Respiratory Distress Syndrome pipeline products will significantly revolutionize the Acute Respiratory Distress Syndrome market dynamics.

Acute Respiratory Distress Syndrome Overview

Acute Respiratory Distress Syndrome (ARDS) is a severe lung condition that causes widespread inflammation and fluid buildup in the lungs, leading to difficulty breathing. It results from various causes such as pneumonia, trauma, sepsis, aspiration, or COVID-19. ARDS can lead to low oxygen levels in the blood, respiratory failure, and may require mechanical ventilation for the patient to breathe. The condition can progress rapidly and is often life-threatening, particularly in critically ill individuals. Treatment typically focuses on supporting breathing, managing the underlying cause, and preventing complications.

Get a Free sample for the Acute Respiratory Distress Syndrome Market Report:

https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market

Acute Respiratory Distress Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Respiratory Distress Syndrome Epidemiology Segmentation:

The Acute Respiratory Distress Syndrome market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Incident Cases of ARDS

• Severity-specific Incident Cases of ARDS

• Incident Cases of ARDS by Risk Factors

Download the report to understand which factors are driving Acute Respiratory Distress Syndrome epidemiology trends @ Acute Respiratory Distress Syndrome Epidemiology Forecast

Acute Respiratory Distress Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Respiratory Distress Syndrome market or expected to get launched during the study period. The analysis covers Acute Respiratory Distress Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Respiratory Distress Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acute Respiratory Distress Syndrome Therapies and Key Companies

• MultiStem (HLCM051): Healios K.K

• ExoFlo (DB-2Q): Direct Biologics

• EB05 (paridiprubart): Edesa Biotech

• Sabizabulin (Veru-111): Veru

• EB05 (paridiprubart) (Edesa Biotech/Light Chain Bio)

• MultiStem (HLCM051): Healios/Nobel Pharma

• Remestemcel-L: Mesoblast

• TP508: Chrysalis BioTherapeutics

• Traumakine: Faron Pharmaceuticals

• BIO-11006: BioMarck Pharmaceuticals

• MultiStem: Athersys

• Solnatide: Apeptico Forschung und Entwicklung GmbH

Discover more about therapies set to grab major Acute Respiratory Distress Syndrome market share @ Acute Respiratory Distress Syndrome Treatment Market

Acute Respiratory Distress Syndrome Drivers

• Rising Incidence of Severe Respiratory Infections: Increasing cases of pneumonia, sepsis, influenza, and other severe respiratory infections are contributing to the growing prevalence of ARDS.

• Growing Burden of Critical Care Admissions: Higher rates of intensive care unit (ICU) admissions due to trauma, infections, and respiratory failure are driving demand for ARDS treatments.

• Advancements in Critical Care Management: Improvements in mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and supportive care technologies are enhancing patient outcomes and market growth.

• Increasing Research and Development Activities: Pharmaceutical companies and research institutions are actively developing novel anti-inflammatory, regenerative, and cell-based therapies for ARDS.

Acute Respiratory Distress Syndrome Barriers

• Limited Availability of Approved Targeted Therapies: Current treatment primarily relies on supportive care, with relatively few approved pharmacological therapies specifically indicated for ARDS.

• Complex Disease Pathophysiology: The heterogeneous nature of ARDS makes drug development challenging and contributes to variable treatment responses.

• High Clinical Trial Failure Rates: Many investigational therapies have failed to demonstrate significant efficacy in late-stage clinical studies, slowing market advancement.

• Difficulty in Early Diagnosis: ARDS can be difficult to diagnose promptly due to overlapping symptoms with other respiratory conditions.

Scope of the Acute Respiratory Distress Syndrome Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Acute Respiratory Distress Syndrome Companies: Veru, Edesa Biotech/Light Chain Bio, Direct Biologics, Healios/Nobel Pharma, Mesoblast, Chrysalis BioTherapeutics, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire français de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and others

• Key Acute Respiratory Distress Syndrome Therapies: Sabizabulin (Veru-111), EB05 (paridiprubart), ExoFlo (DB-001), MultiStem (HLCM051), Remestemcel-L, TP508, Traumakine, BIO-11006, MultiStem, Solnatide, VERU-111, Tradipitant, FP-025, HLCM051(MultiStem), and others

• Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and Acute Respiratory Distress Syndrome emerging therapies

• Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and Acute Respiratory Distress Syndrome market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Acute Respiratory Distress Syndrome Unmet Needs, KOL’s views, Analyst’s views, Acute Respiratory Distress Syndrome Market Access and Reimbursement

To know more about Acute Respiratory Distress Syndrome companies working in the treatment market, visit @ Acute Respiratory Distress Syndrome Clinical Trials and Treatment

Table of Contents

1. Acute Respiratory Distress Syndrome Market Report Introduction

2. Executive Summary for Acute Respiratory Distress Syndrome

3. SWOT analysis of Acute Respiratory Distress Syndrome

4. Acute Respiratory Distress Syndrome Patient Share (%) Overview at a Glance

5. Acute Respiratory Distress Syndrome Market Overview at a Glance

6. Acute Respiratory Distress Syndrome Disease Background and Overview

7. Acute Respiratory Distress Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Respiratory Distress Syndrome

9. Acute Respiratory Distress Syndrome Current Treatment and Medical Practices

10. Acute Respiratory Distress Syndrome Unmet Needs

11. Acute Respiratory Distress Syndrome Emerging Therapies

12. Acute Respiratory Distress Syndrome Market Outlook

13. Country-Wise Acute Respiratory Distress Syndrome Market Analysis (2022–2036)

14. Acute Respiratory Distress Syndrome Market Access and Reimbursement of Therapies

15. Acute Respiratory Distress Syndrome Market Drivers

16. Acute Respiratory Distress Syndrome Market Barriers

17. Acute Respiratory Distress Syndrome Appendix

18. Acute Respiratory Distress Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Respiratory Distress Syndrome Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Veru, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeu

The Diabetic Foot Ulcers Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Diabetic Foot Ulcers Pipeline Insight, 2026″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Foot Ulcers Market.

Get a Free Sample PDF Report to know more about Diabetic Foot Ulcers Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/diabetic-foot-ulcers-pipeline-insight

Some of the key takeaways from the Diabetic Foot Ulcers Pipeline Report:

• Companies across the globe are diligently working toward developing novel Diabetic Foot Ulcers treatment therapies with a considerable amount of success over the years.

• Diabetic Foot Ulcers companies working in the treatment market are Topadur Pharma, Cynata Therapeutics, Transwell Biotech, Aposcience, Ilya Pharma, Microbion Corporation, MediWound, Paracrine, INC., NovaLead Pharma, and others, are developing therapies for the Diabetic Foot Ulcers treatment

• Emerging Diabetic Foot Ulcers therapies in the different phases of clinical trials are- TOP-N53, CYP-006TK, TWB-103, APO-2, ILP100, MBN-101, EscharEx, Adipose-derived regenerative cells, Galnobax, and others are expected to have a significant impact on the Diabetic Foot Ulcers market in the coming years.

• In May 2026, Flen Health Pharma NV, a Belgium-based biopharmaceutical company specializing in wound and skin healing therapies for over 25 years, announced that it has received favorable written feedback from the U.S. FDA following an INTERACT (Initial Targeted Engagement for Regulatory Advice on CBER/CDER Products) meeting for its investigational biologic, VES gel. The FDA provided recommendations regarding the product’s Chemistry, Manufacturing and Controls (CMC) and nonclinical development strategy, representing an important regulatory advancement. This feedback supports the company’s ongoing efforts to progress VES gel, a novel therapy aimed at accelerating the healing of chronic diabetic foot ulcers (DFUs), toward an Investigational New Drug (IND) application submission.

• In November 2025, Kane Biotech Inc. (TSX-V: KNE) announced new clinical and preclinical results showcasing the effectiveness of its FDA-cleared revyve® Antimicrobial Wound Gel and revyve Wound Gel Spray in promoting healing in diabetic foot ulcers and managing burn wound infections. The data were recently presented at two major U.S. medical conferences, including the Diabetic Foot Conference.

• In October 2025, Celularity Inc. reported positive results from its Phase 2 clinical trial of PDA-002, a first-in-class regenerative therapy designed for treating diabetic foot ulcers (DFUs) complicated by peripheral artery disease (PAD). Published in the International Wound Journal, the study revealed that two doses of PDA-002, derived from placenta cells, led to significant wound healing, particularly in patients with PAD. This therapy is especially noteworthy as there are currently no FDA-approved treatments targeting DFUs associated with PAD, a condition impacting around two million people in the U.S. each year. The findings demonstrated enhanced healing rates, fewer complications, and a strong safety profile, underscoring PDA-002’s potential to meet a major unmet need in wound care.

• In July 2025, Eluciderm Inc. has obtained FDA clearance for its Investigational New Drug (IND) application to initiate a Phase I/IIa open-label trial. The study will assess the safety and effectiveness of ELU-42, a topical spray-on solution designed to promote healing in patients with diabetic foot ulcers (DFUs).

• In January 2025, BioStem Technologies, Inc. (OTC: BSEM), a prominent MedTech firm specializing in placental-based products for advanced wound healing, has launched the BR-AM-DFU (BioREtain® Amniotic Membrane – Diabetic Foot Ulcers) clinical trial. This study will assess the effectiveness of Vendaje® compared to the current standard of care in treating non-healing diabetic foot ulcers.

• In January 2025, ION, a clinical-stage regenerative medicine company specializing in exosome-based therapeutics, announced the completion of patient enrollment in its Phase 2 clinical trial for Purified Exosome Product™ (PEP™) to treat Diabetic Foot Ulcers (DFUs). This milestone represents a significant advancement in the company’s efforts to develop innovative therapies for chronic wound care.

Diabetic Foot Ulcers Overview

Diabetic Foot Ulcers (DFUs) are a common and serious complication of diabetes, characterized by open sores or wounds that typically develop on the feet. These ulcers occur due to a combination of factors related to diabetes, including neuropathy (nerve damage), peripheral artery disease (reduced blood flow), and immune system deficiencies, which can impede the body’s ability to heal wounds.

Explore the latest Diabetic Foot Ulcers pipeline insights 2025, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Diabetic Foot Ulcers Clinical Trials

Emerging Diabetic Foot Ulcers Drugs Under Different Phases of Clinical Development Include:

• TOP-N53: Topadur Pharma

• CYP-006TK: Cynata Therapeutics

• TWB-103: Transwell Biotech

• APO-2: Aposcience

• ILP100: Ilya Pharma

• MBN-101: Microbion Corporation

• EscharEx: MediWound

• Adipose-derived regenerative cells: Paracrine, INC.

• Galnobax: NovaLead Pharma

Diabetic Foot Ulcers Route of Administration

Diabetic Foot Ulcers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Diabetic Foot Ulcers Molecule Type

Diabetic Foot Ulcers Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Diabetic Foot Ulcers Pipeline Therapeutics Assessment

• Diabetic Foot Ulcers Assessment by Product Type

• Diabetic Foot Ulcers By Stage and Product Type

• Diabetic Foot Ulcers Assessment by Route of Administration

• Diabetic Foot Ulcers By Stage and Route of Administration

• Diabetic Foot Ulcers Assessment by Molecule Type

• Diabetic Foot Ulcers by Stage and Molecule Type

DelveInsight’s Diabetic Foot Ulcers Report covers around 25+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Diabetic Foot Ulcers product details are provided in the report. Download the Diabetic Foot Ulcers pipeline report to learn more about the emerging Diabetic Foot Ulcers therapies

Some of the key companies in the Diabetic Foot Ulcers Therapeutics Market include:

Key companies developing therapies for Diabetic Foot Ulcers are – Medline, B. Braun, Organogenesis, 3M, Smith & Nephew, Molnlycke Health Care, ConvaTec, Coloplast, Integra LifeSciences, Essity (BSN Medical), and others.

Diabetic Foot Ulcers Pipeline Analysis:

The Diabetic Foot Ulcers pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Foot Ulcers with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Foot Ulcers Treatment.

• Diabetic Foot Ulcers key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Diabetic Foot Ulcers Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Foot Ulcers market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Diabetic Foot Ulcers drugs and therapies

Diabetic Foot Ulcers Pipeline Market Drivers

• Rise in global prevalence of foot ulcers in diabetic patients, increasing research and development activities in the development of biologics, technological advancements are some of the important factors that are fueling the Diabetic Foot Ulcers Market.

Diabetic Foot Ulcers Pipeline Market Barriers

• However, high cost of the advanced wound care therapies, adverse effects associated with the drugs and other factors are creating obstacles in the Diabetic Foot Ulcers Market growth.

Scope of Diabetic Foot Ulcers Pipeline Drug Insight

• Coverage: Global

• Key Diabetic Foot Ulcers Companies: Topadur Pharma, Cynata Therapeutics, Transwell Biotech, Aposcience, Ilya Pharma, Microbion Corporation, MediWound, Paracrine, INC., NovaLead Pharma, and others

• Key Diabetic Foot Ulcers Therapies: TOP-N53, CYP-006TK, TWB-103, APO-2, ILP100, MBN-101, EscharEx, Adipose-derived regenerative cells, Galnobax, and others

• Diabetic Foot Ulcers Therapeutic Assessment: Diabetic Foot Ulcers current marketed and Diabetic Foot Ulcers emerging therapies

• Diabetic Foot Ulcers Market Dynamics: Diabetic Foot Ulcers market drivers and Diabetic Foot Ulcers market barriers

Request for Sample PDF Report for Diabetic Foot Ulcers Pipeline Assessment and clinical trials

Table of Contents

1. Diabetic Foot Ulcers Report Introduction

2. Diabetic Foot Ulcers Executive Summary

3. Diabetic Foot Ulcers Overview

4. Diabetic Foot Ulcers- Analytical Perspective In-depth Commercial Assessment

5. Diabetic Foot Ulcers Pipeline Therapeutics

6. Diabetic Foot Ulcers Late Stage Products (Phase II/III)

7. Diabetic Foot Ulcers Mid Stage Products (Phase II)

8. Diabetic Foot Ulcers Early Stage Products (Phase I)

9. Diabetic Foot Ulcers Preclinical Stage Products

10. Diabetic Foot Ulcers Therapeutics Assessment

11. Diabetic Foot Ulcers Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Diabetic Foot Ulcers Key Companies

14. Diabetic Foot Ulcers Key Products

15. Diabetic Foot Ulcers Unmet Needs

16 . Diabetic Foot Ulcers Market Drivers and Barriers

17. Diabetic Foot Ulcers Future Perspectives and Conclusion

18. Diabetic Foot Ulcers Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Foot Ulcers Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Medline, B. Braun, Organogenesis, 3M, Smith & Nephew, Molnlycke Health

DelveInsight’s “ANCA Vasculitis Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the ANCA Vasculitis, historical and forecasted epidemiology as well as the ANCA Vasculitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the ANCA Vasculitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; ANCA Vasculitis Market Forecast

Some of the key facts of the ANCA Vasculitis Market Report:

• The ANCA Vasculitis market size is expected to expand from approximately USD 1.8 billion in 2025 to nearly USD 3.8 billion by 2036, growing at a CAGR of about 6.5% throughout the forecast period from 2026 to 2036.

• In March 2026, Amgen announced continued commercial expansion of avacopan (TAVNEOS) for ANCA-associated vasculitis following increasing global uptake as a steroid-sparing complement 5a receptor inhibitor. The company continues to generate real-world evidence supporting its role in reducing glucocorticoid-related toxicity in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

• In December 2025, Roche/Genentech highlighted ongoing long-term follow-up data for rituximab (RITUXAN/MabThera) in ANCA-associated vasculitis, reinforcing its continued use as a key therapy for remission induction and maintenance in GPA and MPA patients.

• In October 2025, Chemocentryx (Amgen) presented additional real-world and long-term outcomes data for avacopan (TAVNEOS), demonstrating sustained remission benefits and reduced steroid exposure in patients with severe ANCA-associated vasculitis.

• In June 2025, InflaRx announced continued development progress for vilobelimab (IFX-1), a monoclonal antibody targeting complement C5a, with ongoing interest in complement pathway inhibition as a potential future treatment strategy for ANCA-associated vasculitis.

• Induction typically involves cyclophosphamide or rituximab with high-dose steroids, while maintenance uses methotrexate or azathioprine; newer approved options include TAVNEOS (avacopan) and NUCALA (mepolizumab).

• According to DelveInsight’s estimates, there were approximately 226,000 diagnosed prevalent cases of ANCA vasculitis across the 7MM in 2025, with the United States accounting for the highest share.

• Among EU4, Germany accounted for the largest number of diagnosed prevalent cases of ANCA Vasculitis, followed by Italy, whereas Spain accounted for the lowest cases in 2025.

• In 2025, pANCAs/MPO-ANCAs represented the most commonly diagnosed antibody-specific subtype of AAV in MPA, accounting for approximately 28,000 cases in the US.

• In 2025, the diagnosed prevalent cases of MPA by organ involvement in the UK were highest in renal impairment, followed by other organs such as the lower respiratory tract, cutaneous manifestations, gastrointestinal involvement, nervous system, upper respiratory tract, cardiovascular involvement, and eye involvement.

• Granulomatosis with polyangiitis was found to be more prevalent than any other type of ANCA Vasculitis in the United States (~35,000).

• Key ANCA Vasculitis Companies: CSL, Amgen, NS Pharma, Chemocentryx, Amgen, GlaxoSmithKline, AstraZeneca, Staidson (Beijing) Biopharmaceuticals, Novartis, NovelMed Therapeutics, University of Edinburgh, Alpine Immune Sciences, Inc., Alentis Therapeutics AG, and others

• Key ANCA Vasculitis Therapies: Mepolizumab (NUCALA), Avacopan (TAVNEOS), Depemokimab (GSK3511294), NS-229, TAVNEOS (avacopan), Depemokimab (GSK3511294), FASENRA (benralizumab), BDB-001 injection, Avacopan, Iptacopan, NM8074, Sparsentan, povetacicept, Rituximab, and others

• The ANCA Vasculitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage ANCA Vasculitis pipeline products will significantly revolutionize the ANCA Vasculitis market dynamics.

ANCA Vasculitis Overview

ANCA Vasculitis (AAV) is a group of autoimmune diseases that cause inflammation of blood vessels, leading to damage in various organs, including the kidneys, lungs, and upper respiratory tract. The condition is characterized by the presence of antineutrophil cytoplasmic antibodies (ANCA) in the blood, which target and attack certain white blood cells, causing vessel inflammation. AAV includes conditions like granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Symptoms often include fatigue, fever, weight loss, and organ-specific signs depending on the affected area. Treatment usually involves immunosuppressive drugs to reduce inflammation and manage symptoms

Get a Free sample for the ANCA Vasculitis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/anca-vasculitis-market

ANCA Vasculitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

ANCA Vasculitis Epidemiology Segmentation:

The ANCA Vasculitis market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of ANCA Vasculitis

• Type-specific Diagnosed Prevalent Cases of ANCA Vasculitis

• Severity-specific Diagnosed Prevalence of ANCA Vasculitis

• Diagnosed Prevalent Cases of ANCA Vasculitis by Organ Involvement

• Diagnosed Prevalent Cases of ANCA Vasculitis by Antibody Type

Download the report to understand which factors are driving ANCA Vasculitis epidemiology trends @ ANCA Vasculitis Epidemiology Forecast

ANCA Vasculitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the ANCA Vasculitis market or expected to get launched during the study period. The analysis covers ANCA Vasculitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the ANCA Vasculitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

ANCA Vasculitis Therapies and Key Companies

• Mepolizumab (NUCALA): GlaxoSmithKline

• Avacopan (TAVNEOS): CSL/Amgen

• Depemokimab (GSK3511294): GlaxoSmithKline

• NS-229: NS Pharma

• TAVNEOS (avacopan): Chemocentryx/Amgen

• Depemokimab (GSK3511294): GlaxoSmithKline

• FASENRA (benralizumab): AstraZeneca

• BDB-001 injection: Staidson (Beijing) Biopharmaceuticals

• Avacopan: Amgen

• Iptacopan: Novartis

• NM8074: NovelMed Therapeutics

• Sparsentan: University of Edinburgh

• povetacicept: Alpine Immune Sciences, Inc.

• Rituximab: Alentis Therapeutics AG

Discover more about therapies set to grab major ANCA Vasculitis market share @ ANCA Vasculitis Treatment Landscape

ANCA Vasculitis Market Drivers

• Increasing Prevalence and Diagnosis of Autoimmune Diseases: Improved awareness and advancements in diagnostic testing are leading to earlier detection of ANCA-associated vasculitis (AAV), supporting treatment demand.

• Growing Adoption of Targeted Therapies: The introduction of biologics, B-cell-targeted therapies, and complement pathway inhibitors is improving disease management and expanding treatment options.

• Rising Research and Clinical Trial Activity: Ongoing investments in autoimmune disease research are accelerating the development of innovative therapies for ANCA vasculitis.

• Advancements in Diagnostic Technologies: Improved ANCA testing, biomarker identification, and disease-monitoring tools are enabling more accurate diagnosis and personalized treatment approaches.

ANCA Vasculitis Market Barriers

• Rare Disease Population: The relatively low prevalence of ANCA vasculitis limits the overall patient pool and market size.

• High Cost of Advanced Therapies: Biologics and targeted immunotherapies can be expensive, creating affordability and access challenges in certain regions.

• Risk of Treatment-Related Adverse Events: Long-term immunosuppression may increase the risk of infections, malignancies, and other complications.

• Diagnostic Delays and Disease Complexity: Nonspecific symptoms and disease heterogeneity can result in delayed diagnosis and treatment initiation.

Scope of the ANCA Vasculitis Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key ANCA Vasculitis Companies: GlaxoSmithKline, CSL, Amgen, NS Pharma, Chemocentryx, Amgen, AstraZeneca, Staidson (Beijing) Biopharmaceuticals, Novartis, NovelMed Therapeutics, University of Edinburgh, Alpine Immune Sciences, Inc., Alentis Therapeutics AG, and others

• Key ANCA Vasculitis Therapies: Mepolizumab (NUCALA), Avacopan (TAVNEOS), Depemokimab (GSK3511294), NS-229, TAVNEOS (avacopan), Depemokimab (GSK3511294), FASENRA (benralizumab), BDB-001 injection, Avacopan, Iptacopan, NM8074, Sparsentan, povetacicept, Rituximab, and others

• ANCA Vasculitis Therapeutic Assessment: ANCA Vasculitis current marketed and ANCA Vasculitis emerging therapies

• ANCA Vasculitis Market Dynamics: ANCA Vasculitis market drivers and ANCA Vasculitis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• ANCA Vasculitis Unmet Needs, KOL’s views, Analyst’s views, ANCA Vasculitis Market Access and Reimbursement

To know more about ANCA Vasculitis companies working in the treatment market, visit @ ANCA Vasculitis Clinical Trials and Therapeutic Assessment

Table of Contents

1. ANCA Vasculitis Market Report Introduction

2. Executive Summary for ANCA Vasculitis

3. SWOT analysis of ANCA Vasculitis

4. ANCA Vasculitis Patient Share (%) Overview at a Glance

5. ANCA Vasculitis Market Overview at a Glance

6. ANCA Vasculitis Disease Background and Overview

7. ANCA Vasculitis Epidemiology and Patient Population

8. Country-Specific Patient Population of ANCA Vasculitis

9. ANCA Vasculitis Current Treatment and Medical Practices

10. ANCA Vasculitis Unmet Needs

11. ANCA Vasculitis Emerging Therapies

12. ANCA Vasculitis Market Outlook

13. Country-Wise ANCA Vasculitis Market Analysis (2022–2036)

14. ANCA Vasculitis Market Access and Reimbursement of Therapies

15. ANCA Vasculitis Market Drivers

16. ANCA Vasculitis Market Barriers

17. ANCA Vasculitis Appendix

18. ANCA Vasculitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ANCA Vasculitis Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | CSL, Amgen, NS Pharma, Amgen, GlaxoSmithKline, AstraZeneca, Chemocentry, Staidson (Beijing) Biopharma

DelveInsight’s “Adult Myopia Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Adult Myopia, historical and forecasted epidemiology as well as the Adult Myopia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Adult Myopia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Adult Myopia Market Forecast

Some of the key facts of the Adult Myopia Market Report:

• The Adult Myopia market size is anticipated to grow with a significant CAGR during the study period (2022-2036).

• Myopia and high myopia are projected to show a significant increase in prevalence globally, affecting nearly 5 billion people and 1 billion people, respectively, by 2050.

• Average progression rates demonstrated a gradual decline with advancing age; however, the most substantial and clinically significant myopia progression was observed between 20 and 30 years of age.

• The prevalence of myopia ranges between 1% and 78.4% across studies reported in the 21st century. Although myopia is more prevalent in East Asia, global prevalence has increased from 1.4 billion in 2000 and is projected to reach 4.8 billion by 2050.

• Myopia progression is likely to continue into early adulthood. At age 18, although nearly 75% of myopes are stable, around 25% continue progressing, and approximately 20% of individuals in their 20s may experience progression of at least 1 diopter (D).

• According to WHO-based prevalence projections, myopia and high myopia are expected to affect 52% (4.9 billion) and 10% (925 million) of the global population, respectively, by 2050, representing a major increase from 2010 estimates of 27% (1.9 billion) and 2.8% (170 million), respectively.

• Key Adult Myopia Companies: Novartis, Regeneron Pharmaceuticals, and others

• Key Adult Myopia Therapies: LUCENTIS, EYLEA, and others

• The Adult Myopia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Adult Myopia pipeline products will significantly revolutionize the Adult Myopia market dynamics.

Adult Myopia Overview

Adult Myopia is a common refractive eye disorder in which distant objects appear blurry while near objects remain clear. It occurs when the eyeball is elongated or the cornea is excessively curved, causing light rays to focus in front of the retina rather than directly on it. Although myopia often develops during childhood, it can continue to progress or emerge in adulthood due to genetic factors, prolonged near-work activities, and increased digital screen exposure.

Get a Free sample for the Adult Myopia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/adult-myopia-market

Adult Myopia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Adult Myopia Epidemiology Segmentation:

The Adult Myopia market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalent Population of Adult Myopia

• Prevalence of Myopic Choroidal Neovascularization

Download the report to understand which factors are driving Adult Myopia epidemiology trends @ Adult Myopia Epidemiology Forecast

Adult Myopia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adult Myopia market or expected to get launched during the study period. The analysis covers Adult Myopia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Adult Myopia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Adult Myopia Therapies and Key Companies

• LUCENTIS: Novartis

• EYLEA: Regeneron Pharmaceuticals

Discover more about therapies set to grab major Adult Myopia market share @ Adult Myopia Treatment Landscape

Adult Myopia Market Drivers

• Rising Prevalence of Myopia Worldwide: Increasing rates of myopia among adults, particularly in urban populations, are driving demand for vision correction and myopia management solutions.

• Growing Digital Screen Usage: Prolonged use of smartphones, computers, and digital devices is contributing to eye strain and myopia progression, increasing the need for treatment options.

• Increasing Awareness of Vision Health: Greater awareness regarding the long-term complications of high myopia is encouraging early diagnosis and treatment.

• Advancements in Myopia Management Technologies: Innovations in contact lenses, spectacle lenses, refractive surgery, and pharmaceutical interventions are expanding treatment choices for adult patients.

Adult Myopia Market Barriers

• High Cost of Advanced Treatment Options: Premium contact lenses, refractive surgeries, and specialized myopia management therapies may be unaffordable for some patients.

• Limited Awareness in Certain Regions: Lack of awareness regarding myopia progression and associated complications can delay diagnosis and treatment.

• Variability in Treatment Outcomes: Individual differences in disease progression and response to treatment may affect the effectiveness of available therapies.

• Reimbursement Challenges: Many myopia management products and procedures may not be fully covered by insurance or reimbursement programs.

Scope of the Adult Myopia Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Adult Myopia Companies: Novartis, Regeneron Pharmaceuticals, and others

• Key Adult Myopia Therapies: LUCENTIS, EYLEA, and others

• Adult Myopia Therapeutic Assessment: Adult Myopia current marketed and Adult Myopia emerging therapies

• Adult Myopia Market Dynamics: Adult Myopia market drivers and Adult Myopia market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Adult Myopia Unmet Needs, KOL’s views, Analyst’s views, Adult Myopia Market Access and Reimbursement

To know more about Adult Myopia companies working in the treatment market, visit @ Adult Myopia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Adult Myopia Market Report Introduction

2. Executive Summary for Adult Myopia

3. SWOT analysis of Adult Myopia

4. Adult Myopia Patient Share (%) Overview at a Glance

5. Adult Myopia Market Overview at a Glance

6. Adult Myopia Disease Background and Overview

7. Adult Myopia Epidemiology and Patient Population

8. Country-Specific Patient Population of Adult Myopia

9. Adult Myopia Current Treatment and Medical Practices

10. Adult Myopia Unmet Needs

11. Adult Myopia Emerging Therapies

12. Adult Myopia Market Outlook

13. Country-Wise Adult Myopia Market Analysis (2022–2036)

14. Adult Myopia Market Access and Reimbursement of Therapies

15. Adult Myopia Market Drivers

16. Adult Myopia Market Barriers

17. Adult Myopia Appendix

18. Adult Myopia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Adult Myopia Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Novartis, Regeneron Pharmaceuticals

DelveInsight’s report, “Acute Pain Market Insights, Epidemiology, and Market Forecast-2036” provides a comprehensive analysis of the Acute Pain landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Acute Pain market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Acute Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Pain Market Forecast

Some of the key facts of the Acute Pain Market Report:

• The Acute Pain market is anticipated to increase from approximately USD 4.5 billion in 2025 to around USD 15.5 billion by 2036, registering a compound annual growth rate (CAGR) of 12% during the forecast period from 2026 to 2036.

• In February 2026, Cidara Therapeutics announced MK-1406 (CD388) is currently being evaluated in the Phase III ANCHOR study (NCT07159763).

• In January 2026, Merck announced The company has successfully completed a cash tender offer, conducted via its subsidiary, for the acquisition of all outstanding common shares of Cidara Therapeutics.

• In March 2026, Cocrystalpharma announced The company plan to continue development of oral CC-42344 as a treatment for pandemic and seasonal Acute pain with an additional Phase IIa study.

• In February 2026, The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorisation for mCombriax, a vaccine developed by Moderna, for the prevention of influenza disease.

• In April 2025, Roche announced that New England Journal of Medicine (NEJM) has published a detailed analysis of the phase III CENTERSTONE trial of Xofluza showing a reduction in the transmission of influenza viruses.

• The total number of incident cases of acute pain in the 7MM were around 181,208,000 in 2025.

• The total incident cases of acute pain in the US were around 87,410,000 in 2025. These cases are anticipated to increase in the upcoming years.

• In 2025, approximately 13% of the incident cases of acute pain were reported in Germany.

• In 2025, type-specific incident cases of acute pain in the 7MM comprised 89,907,500; 44,622,400; and 139,849,200 cases for postoperative pain, trauma pain, and acute medical illness, respectively.

• In 2025, there were ~20%; ~15% and ~10% cases for mild, moderate and severe, respectively, in Japan out of 7MM.

• In Germany in 2025, approximately 20% of acute pain cases were classified as mild, 15% as moderate, and around 10% as severe out of 7MM.

• Key Acute Pain Companies: Vertex Pharmaceuticals, Heron Therapeutics, Neumentum, Cali Biosciences, PainReform, and others.

• Key Acute Pain Therapies: JOURNAVX (suzetrigine), ZYNRELEF (bupivacaine and meloxicam), NTM-001, CPL-01, PRF-110, and others

• The Acute Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Pain pipeline products will significantly revolutionize the Acute Pain market dynamics.

• In 2023, type-specific incident cases of Acute Pain in the United States were distributed as approximately 60% for trauma-related pain and 40% for other causes.

• In the United States, severity-specific incident cases of Acute Pain were highest for moderate pain, totaling approximately 25 million cases in 2023.

• In the seven major markets, moderate to severe cases accounted for approximately 60% of the total diagnosed cases in 2023.

Acute Pain Overview

Acute Pain is the immediate pain experienced by patients following a surgical procedure, typically lasting from a few hours to several days. It results from tissue injury, inflammation, and nerve stimulation caused during surgery. The intensity and duration of pain can vary depending on the type of surgery, patient health, and individual pain tolerance.

Get a Free sample for the Acute Pain Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/acute-pain-market

Acute Pain Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Pain Epidemiology Segmentation:

The Acute Pain market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Incident Cases of Acute Pain

• Total Incident Cases of Acute Pain by Type

• Severity Specific Incident Cases of Acute Pain

• Total Treated CasesIn of Acute Pain

Download the report to understand which factors are driving Acute Pain epidemiology trends @ Acute Pain Epidemiology Forecast

Acute Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Pain market or expected to get launched during the study period. The analysis covers Acute Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acute Pain Therapies and Key Companies

• JOURNAVX (suzetrigine): Vertex Pharmaceuticals

• ZYNRELEF (bupivacaine and meloxicam): Heron Therapeutics

• NTM-001: Neumentum

• CPL-01: Cali Biosciences

• PRF-110: PainReform

Discover more about therapies set to grab major Acute Pain market share @ Acute Pain Treatment Landscape

Acute Pain Market Drivers

• Rising Number of Surgical Procedures: Increasing volumes of orthopedic, cardiovascular, cosmetic, and general surgeries are driving demand for effective acute pain management therapies.

• Growing Incidence of Trauma and Injury Cases: Higher rates of road accidents, sports injuries, fractures, and emergency room visits are contributing to the need for rapid pain relief solutions.

• Advancements in Non-Opioid Pain Management: Development of novel non-opioid analgesics and multimodal pain management approaches is expanding treatment options and improving patient outcomes.

• Increasing Focus on Enhanced Recovery After Surgery (ERAS) Programs: Hospitals are adopting ERAS protocols that emphasize effective postoperative pain control and reduced hospital stays.

Acute Pain Market Barriers

• Concerns Regarding Opioid Abuse and Dependence: Strict regulations and concerns over addiction risks associated with opioid analgesics may limit their utilization.

• Stringent Regulatory Requirements: Regulatory agencies require extensive safety and efficacy data, increasing development timelines and costs for new pain therapies.

• Side Effects Associated with Pain Medications: Adverse effects such as nausea, gastrointestinal complications, respiratory depression, and sedation can impact treatment adoption.

• Availability of Generic Alternatives: The widespread presence of low-cost generic pain medications creates pricing pressure for branded products.

Scope of the Acute Pain Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Acute Pain Companies: Vertex Pharmaceuticals, Heron Therapeutics, Neumentum, Cali Biosciences, PainReform, and others

• Key Acute Pain Therapies: JOURNAVX (suzetrigine), ZYNRELEF (bupivacaine and meloxicam), NTM-001, CPL-01, PRF-110, and others

• Acute Pain Therapeutic Assessment: Acute Pain current marketed and Acute Pain emerging therapies

• Acute Pain Market Dynamics: Acute Pain market drivers and Acute Pain market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Acute Pain Unmet Needs, KOL’s views, Analyst’s views, Acute Pain Market Access and Reimbursement

To know more about Acute Pain companies working in the treatment market, visit @ Acute Pain Clinical Trials and Therapeutic Assessment

Table of Contents

1. Acute Pain Market Report Introduction

2. Executive Summary for Acute Pain

3. SWOT analysis of Acute Pain

4. Acute Pain Patient Share (%) Overview at a Glance

5. Acute Pain Market Overview at a Glance

6. Acute Pain Disease Background and Overview

7. Acute Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Pain

9. Acute Pain Current Treatment and Medical Practices

10. Acute Pain Unmet Needs

11. Acute Pain Emerging Therapies

12. Acute Pain Market Outlook

13. Country-Wise Acute Pain Market Analysis (2022–2036)

14. Acute Pain Market Access and Reimbursement of Therapies

15. Acute Pain Market Drivers

16. Acute Pain Market Barriers

17. Acute Pain Appendix

18. Acute Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Pain Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Vertex Pharma, Heron Therapeutics, Neumentum, Cali Biosciences